Agro-industrial byproducts for production of the immunosuppressant mycophenolic acid by Penicillium roqueforti under solid-state fermentation: Enhanced production by ultraviolet and gamma irradiation
Agro-industrial byproducts for production of the immunosuppressant mycophenolic acid by Penicillium roqueforti under solid-state fermentation: Enhanced production by ultraviolet and gamma irradiation
复制标题
DOI：
10.1016/j.bcab.2019.01.053
复制
发表时间：
2019-03-01
影响因子：
4
通讯作者：
Ismaiel, Ahmed A.
中科院分区：
文献类型：
--
作者：
El-Sayed, El-Sayed R.;Ahmed, Ashraf S.;Ismaiel, Ahmed A.
对两株罗克福青霉（Penicillium roqueforti，AG 101和LG 109）固态发酵生产霉酚酸（MPA）的不同农用工业原料进行了筛选。甘蔗渣、玉米秸秆和米糠是最适宜生产MPA的基质。最大MPA浓度达到初始含水量70%的第一基板和80%的其他基板。用改良的Czapek肉汤富集固体基质促进了比用矿物盐溶液富集的更大的MPA浓度。通过使孢子分别经受UV光（254 nm）照射120和90 min以及0.75 KGy的γ射线，改进AG 101和LG 109菌株以在固体基质上产生更高的显著MPA滴度。两株菌在甘蔗渣上的产酶能力最高，经紫外线和γ射线照射后，产酶能力分别提高了1.57-1.72倍和1.74-1.92倍。这些发现表明未来有可能降低生产发酵药物的成本。
Different agro-industrial materials were screened for their performance on production of mycophenolic acid (MPA) by two strains of Penicillium roqueforti (AG101 and LG109) under solid-state fermentation (SSF). Sugarcane bagasse followed by corn stalks and rice bran were the most favorable substrates supporting the MPA production. The maximum MPA concentration was achieved at initial moisture content 70% for the first substrate and 80% for the other substrates. Enrichment of the solid substrate with a modified Czapek's broth promoted a greater MPA concentration than that enriched with mineral salt solution. The AG101 and LG109 strains were improved to produce higher significant MPA titers on solid substrate by subjecting the spores to irradiation by UV light (254 nm) for 120 and 90 min, respectively; and gamma rays at 0.75 KGy. The highest MPA-producing ability of both irradiated strains was observed on sugarcane bagasse and it was increased by 1.57-1.72 fold when irradiated with UV rays and by 1.74-1.92 fold when irradiated with gamma rays, as compared with the non-irradiated cultures. These findings indicate the future possibility to reduce the cost of producing fermentation-based drugs.